
    
      This study is planned to be carried out in Jiangsu regional multi-center. 83 cases are
      preliminarily expected to be included. The study started in December 2018 and ended in
      December 2019. It is expected that the trial will end in December 2020.

      In the absence of such situations as withdrawal of informed consent, intolerance of drug
      toxicity and side effects, or inappropriateness for further trials, each participant's
      expected time for research and treatment will continue until radiographically confirmed tumor
      progression occurs.
    
  